Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program

Haematologica. 2018 May;103(5):e204-e206. doi: 10.3324/haematol.2017.178798. Epub 2018 Feb 1.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adult
  • Aged
  • Aged, 80 and over
  • Drug Resistance, Neoplasm*
  • Female
  • Follow-Up Studies
  • Humans
  • International Agencies
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Piperidines
  • Prognosis
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Retrospective Studies
  • Salvage Therapy*
  • Survival Rate
  • Young Adult

Substances

  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine